Biliary Tract Cancer Clinical Trials in Los Angeles, California

9 recruitingLos Angeles, California

Showing 19 of 9 trials

Recruiting
Phase 3

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Biliary Tract Cancer
AstraZeneca620 enrolled270 locationsNCT06467357
Recruiting
Phase 1Phase 2

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Lung CancersUrothelial CancerLocally Advanced+5 more
Avenzo Therapeutics, Inc.480 enrolled18 locationsNCT07038343
Recruiting
Phase 2

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Biliary Tract CancerHepatocellular Carcinoma
AstraZeneca294 enrolled60 locationsNCT05775159
Recruiting
Phase 1

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Breast CancerEsophageal CancerGastric Cancer+7 more
SystImmune Inc.280 enrolled17 locationsNCT06293898
Recruiting
Phase 2

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Colorectal, CancerGastric CancerBiliary Tract Cancer+4 more
AstraZeneca454 enrolled95 locationsNCT05489211
Recruiting
Not Applicable

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Liver CancerBiliary Tract CancerColon Cancer+76 more
Cedars-Sinai Medical Center360 enrolled1 locationNCT04907643
Recruiting
Phase 1Phase 2

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Colorectal, CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma
Merck Sharp & Dohme LLC220 enrolled55 locationsNCT06428409
Recruiting
Phase 1Phase 2

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Breast CancerEsophageal CancerGastric Cancer+13 more
Tanabe Pharma America, Inc.27 enrolled6 locationsNCT06943521
Recruiting
Phase 1Phase 2

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Pancreatic Ductal AdenocarcinomaBiliary Tract Cancer (BTC)Gastric or Gastroesophageal Junction Adenocarcinoma
Phanes Therapeutics258 enrolled11 locationsNCT05482893